Search Results

You are looking at 1 - 1 of 1 items for :

  • Pediatrics and Juvenile Medicine x
Clear All
Open access

Henu Kumar Verma, Saikrishna Lakkakula and Bhaskar V.K.S. Lakkakula

well as HbF and thereby reduces acute complications, in terms of both number and severity [ 44 ]. After studying the safety and efficacy of HU therapy in patients with SCA, HU has been approved for the treatment of adult sickle cell patients [ 45 ]. Furthermore, prolonged HU therapy in infants with SCA showed sustained hematologic benefits, reduced acute coronary syndrome (ACS) events, improved growth, and preserved organ function. The Hydroxyurea Safety and Organ Toxicity (HUSOFT) extension study revealed that patients who continued the HU therapy showed better